These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 8427869)
1. Halofuginone: an inhibitor of collagen type I synthesis. Granot I; Halevy O; Hurwitz S; Pines M Biochim Biophys Acta; 1993 Feb; 1156(2):107-12. PubMed ID: 8427869 [TBL] [Abstract][Full Text] [Related]
2. Increased skin tearing in broilers and reduced collagen synthesis in skin in vivo and in vitro in response to the coccidiostat halofuginone. Granot I; Bartov I; Plavnik I; Wax E; Hurwitz S; Pines M Poult Sci; 1991 Jul; 70(7):1559-63. PubMed ID: 1886867 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Halevy O; Nagler A; Levi-Schaffer F; Genina O; Pines M Biochem Pharmacol; 1996 Oct; 52(7):1057-63. PubMed ID: 8831725 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of rat renal fibroblast proliferation by halofuginone. Haran N; Leschinski L; Pines M; Rapoport J Nephron Exp Nephrol; 2006; 104(1):e35-40. PubMed ID: 16735800 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone. Nagler A; Katz A; Aingorn H; Miao HQ; Condiotti R; Genina O; Pines M; Vlodavsky I Kidney Int; 1997 Dec; 52(6):1561-9. PubMed ID: 9407501 [TBL] [Abstract][Full Text] [Related]
6. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. McGaha TL; Phelps RG; Spiera H; Bona C J Invest Dermatol; 2002 Mar; 118(3):461-70. PubMed ID: 11874485 [TBL] [Abstract][Full Text] [Related]
7. Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism. McGaha TL; Kodera T; Spiera H; Stan AC; Pines M; Bona CA Arthritis Rheum; 2002 Oct; 46(10):2748-61. PubMed ID: 12384935 [TBL] [Abstract][Full Text] [Related]
8. Halofuginone: a novel antifibrotic therapy. Pines M; Nagler A Gen Pharmacol; 1998 Apr; 30(4):445-50. PubMed ID: 9522159 [TBL] [Abstract][Full Text] [Related]
9. Growth hormone and insulin-like growth factor I regulate collagen gene expression and extracellular collagen in cultures of avian skin fibroblasts. Granot I; Halevy O; Hurwitz S; Pines M Mol Cell Endocrinol; 1991 Sep; 80(1-3):1-9. PubMed ID: 1659542 [TBL] [Abstract][Full Text] [Related]
10. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model. Nagler A; Genina O; Lavelin I; Ohana M; Pines M Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 1):558-63. PubMed ID: 10076128 [TBL] [Abstract][Full Text] [Related]
11. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. Pines M; Domb A; Ohana M; Inbar J; Genina O; Alexiev R; Nagler A Biochem Pharmacol; 2001 Nov; 62(9):1221-7. PubMed ID: 11705455 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone. Nagler A; Miao HQ; Aingorn H; Pines M; Genina O; Vlodavsky I Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):194-202. PubMed ID: 9012656 [TBL] [Abstract][Full Text] [Related]
13. Suppression of hepatocellular carcinoma growth in mice by the alkaloid coccidiostat halofuginone. Nagler A; Ohana M; Shibolet O; Shapira MY; Alper R; Vlodavsky I; Pines M; Ilan Y Eur J Cancer; 2004 Jun; 40(9):1397-403. PubMed ID: 15177499 [TBL] [Abstract][Full Text] [Related]
14. Halofuginone--an inhibitor of collagen type I synthesis--prevents postoperative formation of abdominal adhesions. Nagler A; Rivkind AI; Raphael J; Levi-Schaffer F; Genina O; Lavelin I; Pines M Ann Surg; 1998 Apr; 227(4):575-82. PubMed ID: 9563549 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone. Elkin M; Ariel I; Miao HQ; Nagler A; Pines M; de-Groot N; Hochberg A; Vlodavsky I Cancer Res; 1999 Aug; 59(16):4111-8. PubMed ID: 10463616 [TBL] [Abstract][Full Text] [Related]
16. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. Pines M; Knopov V; Genina O; Lavelin I; Nagler A J Hepatol; 1997 Aug; 27(2):391-8. PubMed ID: 9288615 [TBL] [Abstract][Full Text] [Related]
17. Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Gross DJ; Reibstein I; Weiss L; Slavin S; Dafni H; Neeman M; Pines M; Nagler A Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3788-93. PubMed ID: 14506172 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone. Levi-Schaffer F; Nagler A; Slavin S; Knopov V; Pines M J Invest Dermatol; 1996 Jan; 106(1):84-8. PubMed ID: 8592087 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of matrix metalloproteinase-2 expression and bladder carcinoma metastasis by halofuginone. Elkin M; Reich R; Nagler A; Aingorn E; Pines M; de-Groot N; Hochberg A; Vlodavsky I Clin Cancer Res; 1999 Aug; 5(8):1982-8. PubMed ID: 10473075 [TBL] [Abstract][Full Text] [Related]
20. The effect of halofuginone, an inhibitor of collagen type i synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model. Nagler A; Gofrit O; Ohana M; Pode D; Genina O; Pines M J Urol; 2000 Nov; 164(5):1776-80. PubMed ID: 11025768 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]